Kymera Therapeutics vs Suzhou Zelgen Biopharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Kymera Therapeutics Inc (KYMR)

Q3 202625 Jun – 5 Aug 2026

▲3▼1

Kymera's lead drug KT-621 hits key enrollment milestone early, pulling data forward

KT-621 trial enrollment completed early Kymera finished enrolling patients in a mid-stage trial of KT-621 for atopic dermatitis about six months ahead of schedule. That pulls the key data readout forward to the end of 2026, speeding up the path to a possible approval and making the drug more valuable.
This is the core event that drove the stock and is new this period.
Analyst upgrades and price target hikes After the enrollment news, several analysts raised their price targets, with Canaccord lifting its target to $129 from $106. Upgrades can bring in new buyers and support a higher stock price.
Analyst reactions are a direct market driver and new this period.
Strong pipeline and partnership milestones Kymera reported $65 million in second-quarter collaboration revenue, including a $20 million Sanofi milestone and a $45 million Gilead payment. With about $1.5 billion in cash, the company is funded into 2029, reducing the need to raise money and boosting confidence.
Financial strength and partnership validation are new and support the stock.
Insider share sale A board member's venture fund sold nearly 400,000 shares for about $44 million under a pre-arranged plan. While such sales are common, they can signal that a well-informed investor sees limited upside and may weigh on the stock.
This is a real counterweight to the positive news and is new this period.

July 202625 Jun – 5 Aug 2026

▲3▼1

Kymera's lead drug KT-621 hits key enrollment milestone early, pulling data forward

KT-621 trial enrollment completed early Kymera finished enrolling patients in a mid-stage trial of KT-621 for atopic dermatitis about six months ahead of schedule. That pulls the key data readout forward to the end of 2026, speeding up the path to a possible approval and making the drug more valuable.
This is the core event that drove the stock and is new this period.
Analyst upgrades and price target hikes After the enrollment news, several analysts raised their price targets, with Canaccord lifting its target to $129 from $106. Upgrades can bring in new buyers and support a higher stock price.
Analyst reactions are a direct market driver and new this period.
Strong pipeline and partnership milestones Kymera reported $65 million in second-quarter collaboration revenue, including a $20 million Sanofi milestone and a $45 million Gilead payment. With about $1.5 billion in cash, the company is funded into 2029, reducing the need to raise money and boosting confidence.
Financial strength and partnership validation are new and support the stock.
Insider share sale A board member's venture fund sold nearly 400,000 shares for about $44 million under a pre-arranged plan. While such sales are common, they can signal that a well-informed investor sees limited upside and may weigh on the stock.
This is a real counterweight to the positive news and is new this period.

Latest25 Jun – 5 Aug 2026

▲3▼1

Kymera's lead drug KT-621 hits key enrollment milestone early, pulling data forward

KT-621 trial enrollment completed early Kymera finished enrolling patients in a mid-stage trial of KT-621 for atopic dermatitis about six months ahead of schedule. That pulls the key data readout forward to the end of 2026, speeding up the path to a possible approval and making the drug more valuable.
This is the core event that drove the stock and is new this period.
Analyst upgrades and price target hikes After the enrollment news, several analysts raised their price targets, with Canaccord lifting its target to $129 from $106. Upgrades can bring in new buyers and support a higher stock price.
Analyst reactions are a direct market driver and new this period.
Strong pipeline and partnership milestones Kymera reported $65 million in second-quarter collaboration revenue, including a $20 million Sanofi milestone and a $45 million Gilead payment. With about $1.5 billion in cash, the company is funded into 2029, reducing the need to raise money and boosting confidence.
Financial strength and partnership validation are new and support the stock.
Insider share sale A board member's venture fund sold nearly 400,000 shares for about $44 million under a pre-arranged plan. While such sales are common, they can signal that a well-informed investor sees limited upside and may weigh on the stock.
This is a real counterweight to the positive news and is new this period.

Suzhou Zelgen Biopharmaceuticals Co Ltd (688266.CG)

Q3 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

August 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

Latest21 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.